ANRO vs SGE.L
ANRO: Alto Neuroscience is a clinical-stage biotech developing precision medicines for neuropsychiatric conditions by using biomarkers to match patients to targeted therapies. SGE.L: Sage provides cloud-native financial, HR, and payroll software solutions tailored to the needs of small and medium-sized enterprises globally.
Side-by-side fundamentals
| Metric | ANRO | SGE.L | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $34.28 | £10.86 | |
| Market cap as of 2026-08-24 | $1.3B | $13.3B | |
| PEG as of 2026-08-24 | -4.56 | n/a | |
| Net margin as of 2026-08-24 | -4374.8% | n/a | |
| Operating margin as of 2026-08-24 | -5740.9% | n/a | |
| ROE as of 2026-08-24 | -47.2% | n/a | |
| ROA as of 2026-08-24 | -38.8% | n/a | |
| Debt / equity as of 2026-08-24 | 0.08 | n/a | |
| Beta as of 2026-08-24 | 1.19 | n/a | |
| 1-year return as of 2026-08-21 close | +854.9% | -2.5% | ANRO higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.